Full-Time

Staff Engineer

LSS Black Belt

Integra LifeSciences

Integra LifeSciences

1,001-5,000 employees

Regenerative medicine, surgical devices provider

Compensation Overview

$109.3k - $149.5k/yr

+ Bonus + Commission + Equity

Irvine, CA, USA

In Person

Category
Process Engineering
Required Skills
Six Sigma
Requirements
  • Bachelor’s degree in Engineering, Science, or related technical field; advanced degree preferred.
  • 10–15+ years of relevant experience in engineering, manufacturing, quality, supply chain, or operations.
  • Minimum 5 years leading advanced Lean Six Sigma projects with validated cross-functional impact.
  • Demonstrated success in regulated environments (medical device, biotech, pharmaceutical).
  • Expert-level analytical capability and mastery of advanced statistical methods.
  • Strong influencing and leadership skills across global, matrixed teams.
  • Ability to drive enterprise transformation and coach senior leaders.
  • Proven capability in large-scale project and portfolio management.
Responsibilities
  • Lead large-scale, high-complexity Lean Six Sigma initiatives impacting multiple sites, functions, or global value streams.
  • Serve as a technical expert in DMAIC, advanced statistical modeling, and experimental design; independently apply DOE, MSA, Monte Carlo simulation, and multivariate analysis.
  • Develop enterprise project charters, align stakeholders across functions, and remove systemic barriers to execution.
  • Influence long-term operational strategy by identifying structural waste, systemic constraints, and capability gaps.
  • Shape and advance Lean deployment strategy across global operations, ensuring alignment with enterprise priorities.
  • Facilitate major Kaizen events, value-stream redesign initiatives, and cross-site improvement efforts with full autonomy.
  • Lead deployment and maturation of Daily Management Systems at the site and enterprise tier, including system design, capability building, and governance.
  • Provide expert coaching to Tier 1–3 leaders on KPI design, problem‑solving rigor, escalation pathways, and accountability cycles.
  • Design, implement, and sustain standard work systems, visual management, and process controls across functions or sites.
  • Mentor and elevate the capabilities of Sr Engineers, Green Belts, process owners, and future Black Belts.
  • Lead delivery of LSS curriculum, including advanced tools training, belt certification, and hands-on coaching for complex projects.
  • Serve as a role model for enterprise-wide continuous improvement culture, influencing senior leaders and cross-functional teams.
  • Act as a strategic technical partner to Engineering, Quality, Manufacturing, Supply Chain, and Commercial teams.
  • Ensure improvement initiatives meet or exceed regulatory, quality, and compliance requirements with minimal oversight.
  • Collaborate with Finance to validate and forecast benefits across large portfolios and improvement pipelines.
  • Influence cross-functional decision-making by applying data-driven recommendations and systems-level insights.
  • Design enterprise dashboards, advanced control plans, and performance systems to ensure long-term sustainability of improvements.
  • Present concise, strategic updates to executive sponsors, translating statistical insights into business decisions.
  • Lead contributions to global maturity assessments, including evaluation of LSS adoption, operational discipline, and Daily Management effectiveness.

Integra LifeSciences develops medical technologies for tissue repair and regeneration, including tissue-regeneration scaffolds, neurosurgical devices, wound care products, and specialized surgical instruments. Its scaffolds are implanted on wounds to provide a temporary matrix that guides new tissue growth and gradually integrates with the patient's tissue. The company differentiates itself through a diversified, multi-domain portfolio built via acquisitions, spanning regenerative medicine and conventional medical devices. Its goal is to broaden access to regenerative technology and raise standards of care in surgery and tissue repair.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Plainsboro Township, New Jersey

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hit $392 million, beating guidance with 1.3% organic growth.
  • Raised 2026 adjusted EPS guidance to $2.40-$2.50 on tariff benefits and demand.
  • Braintree facility launches June 2026, enabling SurgiMend Q4 relaunch and supply resilience.

What critics are saying

  • Codman perforator recall causes 10 injuries, triggers lawsuits and hospital product bans.
  • FDA warning letter enforces $27 million ship holds, delaying PriMatrix and neurosurgery revenue.
  • Medline captures 20-30% neurosurgery drill market share with defect-free craniotomy kits.

What makes Integra LifeSciences unique

  • Pioneered regenerative medicine with 1996 FDA-approved Integra Artificial Skin from MIT technology.
  • Expands neurosurgery portfolio with Durepair Dura Regeneration Matrix and Mayfield Ghost Base Unit.
  • Diversified across neurosurgery, wound care, and surgical reconstruction via strategic acquisitions.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Integra LifeSciences who can refer or advise you

Benefits

Medical Insurance

Dental Insurance

Vision Insurance

Short-Term Disability

Long-Term Disability

401(k) Retirement Plan

Company News

Yahoo Finance
Feb 26th, 2026
Integra LifeSciences sees 0.7% organic revenue decline in 2025, guides to $1.66B–1.7B for 2026

Integra LifeSciences reported Q4 revenue of $435 million and adjusted earnings per share above guidance midpoint, but faces headwinds in 2025. Full-year revenue reached $1.635 billion with 0.7% organic decline, whilst gross margin fell 260 basis points to 61.9% due to tariffs, quality remediation and supply constraints. For 2026, the company guided revenue of $1.66 billion to $1.7 billion and adjusted EPS of $2.30 to $2.40, excluding potential new tariff impacts. Management expects operating cash flow exceeding $200 million and plans to reduce leverage from 4.5 times to 2.5–3.5 times by year-end. The company highlighted operational improvements including a new operating model, supply-chain resilience and early relaunches of PriMatrix and DuraRepair. A Braintree facility launching by June should support SurgiMend's Q4 2026 return.

Yahoo Finance
Feb 26th, 2026
Integra LifeSciences shares fall 3.5% on weak Q1 revenue forecast despite Q4 beat

Integra LifeSciences shares fell 3.5% after the medical device company issued weak revenue guidance for the first quarter and reported a significant drop in profitability. The company forecast first-quarter revenue of $382.5 million, 2.8% below analyst expectations. Whilst fourth-quarter revenue of $434.9 million and adjusted earnings per share of $0.83 beat expectations, underlying metrics showed deterioration. Revenue declined 1.7% year-over-year, operating margin fell sharply to 5.3% from 14.5% the previous year, and free cash flow was negative $5.4 million compared to positive $21.14 million a year ago. The combination of weak outlook and deteriorating profitability overshadowed the headline beats. Shares are down 6.9% year-to-date and trading 53.3% below their 52-week high.

Yahoo Finance
Feb 26th, 2026
Integra LifeSciences Q4 sales beat estimates but Q1 guidance misses by 2.8%

Integra LifeSciences reported Q4 2025 revenue of $434.9 million, beating analyst estimates by 1% but declining 1.7% year on year. The medical device company's adjusted earnings per share of $0.83 exceeded expectations by 3.7%. However, the company's Q1 2026 revenue guidance of $382.5 million fell 2.8% below analyst estimates. Operating margin dropped to 5.3% from 14.5% in the prior year quarter, whilst free cash flow turned negative at -$5.4 million. Founded in 1989, Integra develops medical technologies for neurosurgery, wound care and surgical reconstruction. The company has struggled with tepid growth, recording just 3.6% compound annual revenue growth over five years. Its organic revenue rose 2.5% year on year in the quarter.

Yahoo Finance
Feb 25th, 2026
Integra LifeSciences to report Q4 earnings tomorrow amid 2.7% revenue decline forecast

Medical device company Integra LifeSciences will report earnings tomorrow, with analysts expecting revenue to decline 2.7% year on year, reversing an 11.5% increase from the same quarter last year. The company missed revenue expectations last quarter, reporting $402.1 million in revenues, up 5.6% year on year. It also significantly missed revenue guidance for the following quarter. Integra has missed Wall Street's revenue estimates multiple times over the past two years. Analysts have generally reconfirmed their estimates over the last 30 days. Integra's shares are up 5.7% over the past month, outperforming the healthcare equipment segment's 1.9% decline. The stock currently trades at $11.70 against an average analyst price target of $15.50.

DECCO, Inc.
Nov 13th, 2025
DECCO Recognized for "Excellence in Construction"

DECCO recognized for "Excellence in Construction" WOBURN, MA - The Massachusetts Chapter of Associated Builders and Contractors (ABC MA) congratulates DECCO for earning an Eagle Award at the 33rd annual Excellence in Construction Awards for their outstanding work on Integra Life Sciences' Project Revere. Nearly 250 ABC members gathered at the Four Points by Sheraton Hotel in Norwood on November 6th to recognize and celebrate the very best construction projects their companies have to offer. This year's applicant pool was particularly competitive, with each winner selected for the high standards of craftsmanship, safety and quality delivered by talented merit shop workers using the efficient merit shop approach. "We are proud to recognize the outstanding work of our member contractors through the ABC Excellence in Construction Awards," said ABC MA President Greg Beeman. "The winning contractors maintained a constant focus on meeting their clients' needs and set a high bar for craftsmanship, quality and safety." The Eagle Award DECCO won for Project Revere is the pinnacle of achievement. It recognizes overall excellence in project execution, craftsmanship, safety, innovative elements and challenges, and client satisfaction. The Massachusetts Chapter of Associated Builders and Contractors is the largest construction trade association in the Commonwealth, representing nearly 500 local general contractor, subcontractor, supplier and associate members that employ over 20,000 workers throughout Massachusetts.